Brief Summary

Competition Law — Merger Approval — Conditional approval of merger between Nestlé S.A. and Pfizer's infant nutrition business — Competition Tribunal assessing competition concerns due to high market concentration — Conditional remedy involving transitional re-branding to mitigate anti-competitive effects — Tribunal finding that proposed remedy adequately addresses identified concerns and allows for market entry by third parties.

Comprehensive Summary

Summary of Judgment

1. Introduction

These proceedings concerned the approval of a large merger before the Competition Tribunal of South Africa. The matter arose from a worldwide acquisition by Nestlé S.A. of Pfizer Inc.’s infant nutrition interests, with the South African component relating to the infant nutrition business conducted locally under Pfizer’s branding and associated assets and rights.

The primary acquiring firm was Nestlé S.A. (through its South African subsidiary, Nestlé South Africa (Pty) Ltd), and the primary target firm was the infant nutrition business of Pfizer Inc. The Tribunal was asked to determine whether the merger could be approved under the Competition Act, and if so, whether approval should be unconditional or subject to conditions addressing competition concerns identified by the competition authorities.

The Competition Commission investigated the transaction and, on 14 December 2012, recommended that the Tribunal approve the merger subject to conditions described as a transitional re-branding remedy. The Tribunal convened a pre-hearing on 16 January 2013, during which it directed the parties to address how the proposed conditions would work in practice, why they would address the competition concerns, and why they were preferable to a permanent divestiture remedy. The merger hearing took place on 6 February 2013, an order was issued on 11 February 2013 granting conditional approval, and the Tribunal’s reasons were issued on 18 March 2013.

The general subject-matter of the dispute was whether, given the high concentration in South African infant milk formula markets and the resulting risk that the merger would effectively reduce significant competitors, the transaction could be permitted if accompanied by a remedy that preserved competition both in the short term and over the longer term.

2. Material Facts

Nestlé is a global nutrition, health and wellness group producing and selling a wide variety of food and beverage products, including infant nutrition products such as infant formula and toddler milks. Pfizer Nutrition was a global paediatric nutrition business, with brands including S-26, SMA, and Infasoy, and with maternal supplement products (including Centrum Materna). Pfizer’s decision to sell its nutrition business followed its acquisition of Wyeth’s assets in 2009 and an expressed intention to refocus on core pharmaceuticals; the disposal took place via a global auction process in which Nestlé was the successful bidder.

The Commission identified horizontal overlap between the merging parties in infant milk formula (IMF) and, to a lesser extent, maternal supplements. However, the Commission ultimately concluded that maternal supplement products were complementary rather than competitive in the manner relevant to the assessment, and the Tribunal therefore did not consider that market further for purposes of the decision.

The Commission identified several IMF-related product market segments, including starter formula (0–6 months), follow-on (7–12 months), growing-up milk (12 months to 5 years), and specialty milks for particular infant needs. The merging parties proposed broader product market definitions and disputed whether specialty infant formula constituted a separate market. The parties and the Commission also differed on geographic scope (national versus potentially international). The Tribunal recorded that, in light of the remedy proposed, it was not necessary to make definitive findings on market delineation.

A central undisputed factual premise for the Tribunal’s analysis was that, regardless of whether the market was defined narrowly or broadly, the relevant South African IMF markets were highly concentrated and effectively comprised only a small number of significant competitors. On the Commission’s figures, Nestlé’s market share exceeded 70% across the relevant segments, with Aspen occupying an estimated share of around 20% and Pfizer having a smaller share (estimated in a low range). In specialty products, Abbott was also present. The Commission assessed the merger in substance as a three-to-two transaction in the relevant markets, leaving Aspen as the only significant remaining competitor if Pfizer’s competitive constraint were removed.

The parties initially offered an earlier version of a transitional re-branding remedy at filing stage. After market enquiries and feedback (including from market participants and from Lactalis’ experience in a comparable re-branding divestiture in France), the Commission rejected the earlier proposal as insufficient. In response, the merging parties proposed a revised remedy, which the Commission accepted and recommended.

The Tribunal accepted as material that, by the time of the South African hearing, the transaction had already become effective in several jurisdictions, and that Nestlé had already obtained ownership of Pfizer’s infant nutrition business (including trade marks) in various countries outside South Africa as part of the global transaction. The Tribunal also accepted evidence that South Africa represented a very small proportion of the global turnover of the acquired assets, and that the strategic rationale for Nestlé’s acquisition was principally to expand in markets such as China and parts of Asia, rather than to expand in South Africa where Nestlé already held a large position.

The revised remedy, as described to and accepted by the Tribunal, was structured to require a prompt on-sale of the South African Pfizer infant nutrition business assets to an as-yet unidentified third-party purchaser, accompanied by licensing and transition arrangements intended to enable that purchaser to operate the business immediately while re-branding over time, and to ensure that, after a “black-out” period, Nestlé could regain unencumbered ownership and use of Pfizer’s trade marks globally while competition in South Africa would be protected through the purchaser’s re-branded operations.

3. Legal Issues

The central legal questions were whether the merger, in the context of highly concentrated IMF markets, raised competition concerns requiring intervention, and if so, whether the Tribunal could approve the transaction subject to conditions that adequately addressed the identified competition concerns.

The dispute primarily concerned the application of competition law principles to the facts, including an assessment of market concentration, the likely effect of the merger on competitive constraints, and whether the proposed remedy would maintain effective competition. To the extent that market definition was debated, the Tribunal treated those questions as not requiring final determination because the remedy was framed to address concerns on either formulation.

A further issue, treated as integral to the remedy assessment, was whether a transitional re-branding remedy was preferable to a permanent divestiture in circumstances where the transaction was global and where permanent local transfer of trade marks would create split ownership of international brands, with attendant risks identified in the evidence.

Public interest issues were also considered, but the factual position presented was that the transaction would not adversely affect employment and raised no other public interest concerns.

4. Court’s Reasoning

The Tribunal approached the matter on the basis that it was common cause between the Commission and the merging parties that the transaction raised competition concerns requiring a remedy. It therefore focused its reasoning on whether the proposed conditions were appropriately designed to address those concerns and whether the remedy was workable and sufficient in both the short term (preserving the pre-merger competitive constraint) and the longer term (facilitating sustainable competition after re-branding).

A substantial component of the Tribunal’s reasoning concerned the comparison between a permanent divestiture and a transitional re-branding remedy. The Commission’s evidence highlighted that a divestiture without re-branding could resemble a long-term or perpetual IP-based arrangement, potentially creating ongoing contractual relationships between competitors and raising risks of coordination or manipulation through licensing. The Tribunal also recorded evidence that a full divestiture of IP (trade marks and other rights) would lead to the opposite challenge: split ownership of internationally recognised trade marks, with risks including reputational spillover (where an incident affecting one owner’s version of the brand might harm the other), and “free-riding” (where one owner benefits from the other’s investment in the brand and R&D). The Tribunal accepted that these split-ownership risks would be enduring in a permanent divestiture scenario, whereas a time-bound re-branding approach could remove brand-origin confusion over time.

In applying these considerations, the Tribunal reasoned that the revised transitional re-branding remedy would, after completion of the re-branding period and the black-out period, eliminate continued dual exposure of consumers to the Pfizer trade marks in South Africa. It accepted that obliging the purchaser/licensee to adopt its own trade marks within the specified period would produce a stand-alone competitor without continued association to Pfizer branding in the long run. The Tribunal also accepted that the black-out period would reduce or eliminate residual market recognition of the Pfizer trade marks in South Africa, while preserving product quality and continuity through access to process technology and know-how.

The Tribunal assessed the revised remedy as incorporating multiple elements aimed at ensuring that the purchaser could “step into the shoes” of Pfizer immediately while developing independent branding and capability. These elements included long-term exclusive licences to use the Pfizer trade marks for the transitional period, a subsequent long black-out period during which Nestlé could not use those marks in South Africa, access to formulations and process technology (including trade secrets and know-how), provisions relating to pipeline products, access to clinical and product trial results for a defined period, transfer of marketing and promotional materials and operational records, and obligations regarding the transfer or availability of relevant personnel. The Tribunal accepted that these measures responded to market participants’ concerns about the risks and difficulty of re-branding in infant nutrition markets, the role of health care practitioners as a route to market, and the need for ongoing investment and product development capacity.

The Tribunal specifically considered, and recorded, the concern that the remedy involved an ongoing contractual relationship between Nestlé and the purchaser/licensee, which could in principle create coordination risks. It accepted the Commission’s position that this interaction would be limited in duration and would end once re-branding was complete, and it noted that the purchaser transaction would itself be subject to a further merger notification process. The Tribunal also dealt with a trade mark maintenance concern raised during the hearing regarding what sales might be required to maintain trade mark registrations, recording Nestlé’s undertaking to notify the Commission of such sales and incorporating that undertaking into the conditions.

An important evaluative aspect of the Tribunal’s reasoning was its emphasis that the remedy’s success depended substantially on the identity and characteristics of the purchaser. The Tribunal considered it essential that the purchaser be independent of Nestlé and have the financial resources, expertise, and incentives to maintain and develop the divested business as a viable competitor. While the proceedings were uncontested and no third parties intervened, the Tribunal nevertheless noted that the purchaser would be subject to scrutiny via the merger notification process contemplated in the Act, and it expressed the view that the Commission and merging parties should assess any purchaser against the objective of maintaining short-term competitive structure while building a credible long-term competitor.

On public interest, the Tribunal accepted the parties’ confirmation that there would be no adverse employment effects and found no other public interest issues arising.

5. Outcome and Relief

The Tribunal conditionally approved the merger. The approval was made subject to the final set of tendered conditions, reflecting the revised transitional re-branding remedy (as enhanced following questions raised by the Tribunal). The conditions were recorded as being set out in full in Annexures X and Y to the Tribunal’s order/decision.

The reasons do not record any separate or adverse costs order.

Cases Cited

No reported case authorities were cited in the Tribunal’s reasons.

Legislation Cited

Competition Act 89 of 1998 (as amended), including section 13A.

Rules of Court Cited

No rules of court were cited in the Tribunal’s reasons.

Held

The Tribunal held that the merger raised competition concerns requiring a remedy, and that the revised transitional re-branding remedy (providing for the on-sale of the South African Pfizer infant nutrition business to an approved purchaser and extensive licensing/transition arrangements, including re-branding and black-out periods) was acceptable to address those concerns. The merger was therefore approved subject to the agreed conditions set out in Annexures X and Y, with the purchaser transaction to be subject to the merger notification process under the Competition Act.

LEGAL PRINCIPLES

The decision applied the principle that, where a merger in a highly concentrated market would likely remove an existing competitive constraint, approval may be granted only if accompanied by conditions that adequately prevent the erosion of competitive structure and sustain rivalry over time. The Tribunal’s approach reflected an assessment of both short-term preservation of the pre-merger competitive landscape and longer-term viability of competition following implementation of remedial measures.

The Tribunal accepted that remedies must be assessed not only in terms of formal design but also in terms of practical workability in the relevant industry context. In infant nutrition markets, consumer sensitivity to brand changes, the influence of health care practitioners, and the role of research, development, and pipeline products were treated as practical factors relevant to whether a remedy would sustain competitive constraint.

The Tribunal also applied the principle that remedies involving intellectual property and branding may require careful structuring to avoid ongoing competitive distortions. In particular, the Tribunal accepted that permanent split ownership of international trade marks can create enduring risks (including reputational spillover and free-riding) and that a time-limited transitional re-branding solution can be used to eliminate long-term dual branding and associated confusion while still enabling effective market participation by a divestiture purchaser.

Finally, the Tribunal emphasised that the effectiveness of a divestiture-style remedy depends materially on the suitability of the purchaser. A purchaser must be sufficiently independent and capable, with appropriate resources and incentives, to maintain and develop the divested business as a competitive force, and the purchaser’s acquisition may itself require separate regulatory scrutiny under the merger notification provisions of the Competition Act.

Nestle SA v Infant Nutrition Business of Pfizer Inc (65/LM/Jun12) [2013] ZACT 16; [2013] 1 CPLR 257 (CT) (18 March 2013)